Endocrine Abstracts

Raloxifene (RAL) is a selective estrogen receptor (ER) modulator (SERM) proposed for chemoprevention of breast cancer and osteoporosis. SERMs exert agonist–antagonist effects depending on tissue or ERs expressed. RAL induces apoptosis in both androgen-dependent and independent cell lines, suggesting a selective activation of ERβ and prevalent antagonist effect on ERα in prostate cells (PC). In this study we evaluated effects of estradiol (E2) and RAL on epitheli...